SIXTH AMENDMENT TO THE EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTExclusive Research, Development and License Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled
This Sixth Amendment to Exclusive Research, Development and License Agreement (this “Sixth Amendment”) is made and entered into as of this 29th day of January, 2014 by and among Baxter Healthcare SA, a Swiss corporation having a principal place of business at Postfach, 8010, Zurich, Switzerland (hereinafter “BHSA”) Baxter Healthcare Corporation, a Delaware corporation having a principal place of business at 1 Baxter Parkway, Deerfield, Illinois (“BHC” and together with BHSA, “Baxter”) and Lipoxen Technologies Limited, having a place of business at London Bioscience Innovation Centre, 2 Royal College Street, London NW1 ONH, England (hereinafter “Lipoxen”) to amend the terms of that certain Exclusive Research, Development and License Agreement, dated August 15, 2005 among, Lipoxen and Baxter (the “Agreement”) (as amended). Baxter and Lipoxen are each referred to herein as a “Party” and collectively as the “Parties”.
SIXTH AMENDMENT TO THE EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTExclusive Research, Development and License Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
This Sixth Amendment to Exclusive Research, Development and License Agreement (this “Sixth Amendment”) is made and entered into as of this 29th day of January, 2014 by and among Baxter Healthcare SA, a Swiss corporation having a principal place of business at Postfach, 8010, Zurich, Switzerland (hereinafter “BHSA”) Baxter Healthcare Corporation, a Delaware corporation having a principal place of business at 1 Baxter Parkway, Deerfield, Illinois (“BHC” and together with BHSA, “Baxter”) and Lipoxen Technologies Limited, having a place of business at London Bioscience Innovation Centre, 2 Royal College Street, London NW1 ONH, England (hereinafter “Lipoxen”) to amend the terms of that certain Exclusive Research, Development and License Agreement, dated August 15, 2005 among, Lipoxen and Baxter (the “Agreement”) (as amended). Baxter and Lipoxen are each referred to herein as a “Party” and collectively as the “Parties”.
EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTExclusive Research, Development and License Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled • Illinois
This Agreement (“AGREEMENT”) is made and entered into August 15, 2005 (the “EFFECTIVE DATE”) by and between Lipoxen Technologies Limited, a company registered in England and Wales with company number 03401495 and having its registered office at Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB (“LIPOXEN”); Baxter Healthcare SA (“BHSA”), a corporation organized and existing under the laws of Switzerland, and Baxter Healthcare Corporation (“BHC”) having its principal place of business at One Baxter Parkway, Deerfield, Illinois 60015 (BHSA and BHC collectively referred to as “BAXTER”). LIPOXEN and BAXTER may be referred to herein individually as a “PARTY” and collectively as the “PARTIES.”
SECOND AMENDMENT TO EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTExclusive Research, Development and License Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Amendment”) is made and entered into as of this 28TH day of May, 2009 by and among Lipoxen Technologies Limited, a company registered in England and Wales with company number 03401495 and having its registered office at London Bioscience Innovation Centre, 2 Royal College St., London NWI ONH, England (“Lipoxen”); Baxter Healthcare SA (“BHSA”), a corporation organized and existing under the laws of Switzerland, and Baxter Healthcare Corporation (“BHC”) having its principal place of business at One Baxter Parkway, Deerfield, Illinois 60015 (BHSA and BHC collectively referred to as “Baxter”) to amend the terms of that certain Exclusive Research, Development and License Agreement between the Parties dated August 15, 2005, which was amended pursuant to that certain amendment between the parties dated on or about December 15, 2006 (together the “Agreement”). Lipoxen and Baxter may be referred to herein indi
DATED AUGUST, 10 2010 LIPOXEN TECHNOLOGIES, LTD. - and - BAXTER HEALTHCARE CORPORATION AND BAXTER HEALTHCARE SA AMENDMENT NUMBER FOUR TO THE EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTExclusive Research, Development and License Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
DATED SEPTEMBER, 15 2010 LIPOXEN TECHNOLOGIES, LTD. - and - BAXTER HEALTHCARE CORPORATION AND BAXTER HEALTHCARE SA AMENDMENT NUMBER FIVE TO THE EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTExclusive Research, Development and License Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled
DATED AUGUST, 10 2010 LIPOXEN TECHNOLOGIES, LTD. - and - BAXTER HEALTHCARE CORPORATION AND BAXTER HEALTHCARE SA AMENDMENT NUMBER FOUR TO THE EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTExclusive Research, Development and License Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled
SECOND AMENDMENT TO EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTExclusive Research, Development and License Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled
This SECOND AMENDMENT TO EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Amendment”) is made and entered into as of this 28TH day of May, 2009 by and among Lipoxen Technologies Limited, a company registered in England and Wales with company number 03401495 and having its registered office at London Bioscience Innovation Centre, 2 Royal College St., London NWI ONH, England (“Lipoxen”); Baxter Healthcare SA (“BHSA”), a corporation organized and existing under the laws of Switzerland, and Baxter Healthcare Corporation (“BHC”) having its principal place of business at One Baxter Parkway, Deerfield, Illinois 60015 (BHSA and BHC collectively referred to as “Baxter”) to amend the terms of that certain Exclusive Research, Development and License Agreement between the Parties dated August 15, 2005, which was amended pursuant to that certain amendment between the parties dated on or about December 15, 2006 (together the “Agreement”). Lipoxen and Baxter may be referred to herein indi
EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTExclusive Research, Development and License Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations • Illinois
This Agreement (“AGREEMENT”) is made and entered into August 15, 2005 (the “EFFECTIVE DATE”) by and between Lipoxen Technologies Limited, a company registered in England and Wales with company number 03401495 and having its registered office at Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB (“LIPOXEN”); Baxter Healthcare SA (“BHSA”), a corporation organized and existing under the laws of Switzerland, and Baxter Healthcare Corporation (“BHC”) having its principal place of business at One Baxter Parkway, Deerfield, Illinois 60015 (BHSA and BHC collectively referred to as “BAXTER”). LIPOXEN and BAXTER may be referred to herein individually as a “PARTY” and collectively as the “PARTIES.”
DATED SEPTEMBER, 15 2010 LIPOXEN TECHNOLOGIES, LTD. - and - BAXTER HEALTHCARE CORPORATION AND BAXTER HEALTHCARE SA AMENDMENT NUMBER FIVE TO THE EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTExclusive Research, Development and License Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
